Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients with Relapsed or Refractory Non-small Cell Lung cancer

Phase 2

• Conditions: Relapsed or Refractory Non-small Cell Lung Cancer

• Registration Number: JPRN-UMIN000000501
• Lead Sponsor: Outpatient Oncology Unit Kyoto University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-12
• Study Completion: 2008-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) Active ineterstitial pneumonitis 2) History of using TS-1 or docetaxel 3) Active infectious disease 4) Active hepatitis or hepatocirrhosis 5) Active concomitant malignancy 6) Uncontrollable diabetes 7) Serious cardiac disease 8) Psycologic illness 9) Other severe complications 10) Pleural or pericardial effusion, or ascites requiring treatment 11) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy 12) Regular use of warfarin 13) Regular use of fenitoin or frucitocin 14) High fever 15) Clinical symptom of brain metastases 16) Serious nephropathy and/or edema 17) Regular use of steroid 18) Medical history of serious allergy reactions to any drug 19) Inappropriate patients for this study judged by the physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified